Clinical course of severe esophagitis following bevacizumab therapy
Korean J Intern Med
.
2022 Jan;37(1):243-244.
doi: 10.3904/kjim.2021.143.
Epub 2021 Jun 15.
Authors
Jun-Ho Choi
1
,
Kwangwoo Nam
1
Affiliation
1
Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea.
PMID:
34126704
PMCID:
PMC8747914
DOI:
10.3904/kjim.2021.143
No abstract available
MeSH terms
Bevacizumab / adverse effects
Esophagitis* / chemically induced
Esophagitis* / diagnosis
Esophagitis* / drug therapy
Esophagitis, Peptic*
Humans
Substances
Bevacizumab